TRxADE HEALTH Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TRxADE HEALTH.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare Services earnings growth	27.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

Jul 25

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Mar 30

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Nov 23

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Jul 29

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

Jun 16

SpartanNash and Bonum Health join hands to provide telemedicine services

Jun 07

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

May 22

Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Apr 28

Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Apr 01

Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

Feb 05

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TRxADE HEALTH has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:MEDS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	8	-14	-2	-2	N/A
9/30/2023	9	-4	0	0	N/A
6/30/2023	9	-4	0	0	N/A
3/31/2023	10	-3	-2	-1	N/A
12/31/2022	10	-2	-2	-2	N/A
9/30/2022	10	-3	-4	-3	N/A
6/30/2022	11	-4	-4	-3	N/A
3/31/2022	10	-6	-3	-3	N/A
12/31/2021	10	-5	-3	-3	N/A
9/30/2021	9	-7	-3	-3	N/A
6/30/2021	13	-5	0	0	N/A
3/31/2021	18	-3	-3	-3	N/A
12/31/2020	17	-3	-2	-2	N/A
9/30/2020	17	-1	-2	-2	N/A
6/30/2020	13	-1	-4	-4	N/A
3/31/2020	8	0	0	0	N/A
12/31/2019	7	0	0	0	N/A
9/30/2019	7	0	0	0	N/A
6/30/2019	6	0	0	0	N/A
3/31/2019	4	0	0	0	N/A
12/31/2018	4	0	0	0	N/A
9/30/2018	3	0	0	0	N/A
6/30/2018	3	0	0	0	N/A
3/31/2018	3	0	0	0	N/A
12/31/2017	3	0	0	0	N/A
9/30/2017	3	0	N/A	0	N/A
6/30/2017	3	0	N/A	-1	N/A
3/31/2017	3	-1	N/A	-1	N/A
12/31/2016	2	-1	N/A	-1	N/A
9/30/2016	1	-1	N/A	-2	N/A
6/30/2016	2	-1	N/A	-2	N/A
3/31/2016	3	0	N/A	-2	N/A
12/31/2015	3	0	N/A	-2	N/A
9/30/2015	4	-1	N/A	-1	N/A
6/30/2015	3	-1	N/A	-1	N/A
3/31/2015	2	-2	N/A	-1	N/A
12/31/2014	1	-2	N/A	-1	N/A
9/30/2014	1	-3	N/A	-1	N/A
6/30/2014	1	-3	N/A	-1	N/A
3/31/2014	1	-3	N/A	-1	N/A
12/31/2013	1	-2	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MEDS's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if MEDS's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if MEDS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MEDS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if MEDS's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MEDS's Return on Equity is forecast to be high in 3 years time

TRxADE HEALTH Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus forecasts updated

No longer forecast to breakeven

Price target decreased to US$3.25

Consensus forecasts updated

Consensus EPS estimates fall by 19%

Consensus forecasts updated

Recent updates

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

Price target decreased to US$3.25

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

TRxADE Health prices of $1.8M stock offering

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE Health launches next day delivery services via Trxade prime plus program

TRxADE Health proposes public stock offering

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Consensus EPS estimates fall by 19%

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.92

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

Consensus EPS estimates fall by 54%

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?

Price target decreased to US$7.50

Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates

Price target decreased to US$8.75

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)

SpartanNash and Bonum Health join hands to provide telemedicine services

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

Price target decreased to US$10.00

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00

Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

Price target raised to US$12.17

Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?

New 90-day high: US$6.36

Price target raised to US$12.17

New 90-day low: US$4.56

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020